Using blood cell ratios and procalcitonin to predict outcomes for adults with sepsis in the ICU
Comparison Between Neutrophils to Lymphocytes and Platelets Ratio, Procalcitonin, and Total Leucocytic Count as Indicators of Prognostic Outcome in Septic Patients in the Intensive Care Unit.
This project will test whether routine blood measures—neutrophil-to-lymphocyte-and-platelet ratio, procalcitonin, and total white blood cell count—can help predict outcomes for adults with sepsis in the intensive care unit.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 290 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT07200817 on ClinicalTrials.gov |
What this trial studies
This is an observational ICU study that will collect routine laboratory values (neutrophil-to-lymphocyte-and-platelet ratio, procalcitonin, and total leukocyte count) from adult patients diagnosed with sepsis. Researchers will compare these biomarkers to patients' clinical outcomes such as mortality, organ failure, and length of ICU stay to see which markers best correlate with prognosis. The study excludes patients with pregnancy, malignancy, immunosuppression, hematologic disorders, major trauma or burns, advanced liver cirrhosis, or those on hemodialysis. No investigational treatments are given; data are drawn from standard care blood tests and clinical records.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18–70 who are admitted to the ICU with sepsis (per current sepsis definitions) and who do not have the listed exclusion conditions.
Not a fit: Patients who are pregnant, have active malignancy, are on immunosuppressive therapy, have hematologic disorders, major trauma or burns, Child-Pugh C cirrhosis, or are on hemodialysis are excluded and would not receive benefit from participation.
Why it matters
Potential benefit: If successful, these low-cost, routinely available blood markers could help clinicians identify higher-risk sepsis patients earlier and better target monitoring and treatment.
How similar studies have performed: Previous studies have shown that procalcitonin and neutrophil/lymphocyte-based ratios often correlate with sepsis severity and mortality, but results have been variable and not yet definitive for routine prognostic use.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age from 18 to 70 years old. * Both sexes. * Septic patients (under the third international consensus definitions of sepsis and septic shock). Exclusion Criteria: * Pregnancy * Malignancy * On immunosuppressive therapy * Hematological Disorders * Major Trauma * Major Burns * Child-Pugh Class C Liver Cirrhosis * On Hemodialysis
Where this trial is running
Cairo
- Ain Shams University — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Michael G Farag, Master
- Email: MICHAELFARAG@med.asu.edu.eg
- Phone: 00201278142328
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.